GLICLAZIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H21N3O3S
Molecular Weight	323.411
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2C[C@@H]3CCC[C@@H]3C2

InChI

InChIKey=BOVGTQGAOIONJV-BETUJISGSA-N

InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)/t12-,13+

HIDE SMILES / InChI

Molecular Formula	C15H21N3O3S
Molecular Weight	323.411
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.medicines.org.uk/emc/medicine/31089
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68005907 | https://www.drugs.com/cons/gliclazide.html

Gliclazide (BILXONA®) is an oral sulfonylurea hypoglycemic agent which is used in type 2 diabetes to stimulate insulin production. It differs from other related compounds by an N-containing heterocyclic ring with an endocyclic bond. Gliclazide (BILXONA®) reduces blood glucose levels by stimulating insulin secretion from the beta-cells of the islets of Langerhans. Increase in postprandial insulin and C-peptide secretion persists after two years of treatment. In addition to these metabolic properties, Gliclazide (BILXONA®) has haemovascular properties. It is not available for sale in the United States.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
potassium inwardly rectifying channel, subfamily J, member 11 1 Target ID: 16514.0 Gene Symbol: Kcnj11 Sources: https://www.drugbank.ca/drugs/DB01120	Inhibitor 8504		3.0 mM [Ki]
ATP-binding cassette sub-family C member 8 3 Target ID: CHEMBL1944490 Sources: https://www.drugbank.ca/drugs/DB01120	Inhibitor 8504		50.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 262 Sources: http://www.medicines.org.uk/emc/medicine/31089	Primary		Approved 8583	BILXONA Approved Use Non insulin-dependent diabetes (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose. Launch Date 2015

C_max

Value	Dose	Analyte	Population
2.6 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=16	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.2 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=16	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.6 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.3 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.8 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.5 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.7 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
6.3 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
23.6 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
55.65 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
37.2 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
71.8 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
92.5 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
8.6 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=16	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.3 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=16	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.6 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.1 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.3 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.6 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.4 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.8 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN
20.5 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
8% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=19 \| https://pubmed.ncbi.nlm.nih.gov/6396398/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GLICLAZIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.3% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/400093_3961007F1115_1_022_1F.pdf#page=20		GLICLAZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5% OTHER https://www.medicines.org.uk/emc/product/11631/smpc#PHARMACOKINETIC_PROPS		GLICLAZIDE plasma	Homo sapiens
5% OTHER GOV'T https://mhraproducts4853.blob.core.windows.net/docs/7357945bb5a0c49133c4ea64d51e2fb31ffe976d#page=15		GLICLAZIDE plasma	Homo sapiens

Doses

Dose	Population	Adverse events
2.1 g single, oral Overdose Dose: 2.1 g Route: oral Route: single Dose: 2.1 g Sources: https://pubmed.ncbi.nlm.nih.gov/26150642/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/26150642/	Disc. AE: Metabolic acidosis, Vomiting... AEs leading to discontinuation/dose reduction: Metabolic acidosis (grade 3-4) Vomiting Abdominal pain (grade 3) Hypoglycaemia Encephalopathy Acute kidney injury Haemodynamic instability (grade 3) Distributive shock (grade 3) Sources: https://pubmed.ncbi.nlm.nih.gov/26150642/
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11592575/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11592575/	Disc. AE: Hepatitis, Hemiplegia... AEs leading to discontinuation/dose reduction: Hepatitis Hemiplegia (grade 3) Dysphasia Lethargy Tonic-clonic convulsion Consciousness abnormal Stupor Sources: https://pubmed.ncbi.nlm.nih.gov/11592575/
198 mg 1 times / day multiple, oral Recommended Dose: 198 mg, 1 times / day Route: oral Route: multiple Dose: 198 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15787663/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/15787663/	Other AEs: Hypoglycaemia, Diarrhoea... Other AEs: Hypoglycaemia (10.1%) Diarrhoea (3.4%) Nausea (5.1%) Oedema (4.5%) Dizziness (6.5%) Headache (8.9%) Hypertension (3.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/15787663/

AEs

PubMed

Title	Date	PubMed
Gliclazide-induced acute hepatitis.	2000 Jan	10656221
Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.	2001	11577798
Comparison of the effects of three sulfonylureas on in vivo insulin action.	2001	11455676
Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes.	2001	11268714
Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.	2001 Aug	11837468
Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells.	2001 Aug	11484080
Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.	2001 Aug	11473038
Regulation of glucose transporter 1 expression by gliclazide in rat L6 myoblasts.	2001 Dec	11853362
Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.	2001 Jun	11456286
Gliclazide decreases vascular smooth muscle cell dysfunction induced by cell-mediated oxidized low-density lipoprotein.	2001 Jun	11398146
Characteristics of pancreatic beta-cell secretion in Type 2 diabetic patients treated with gliclazide and glibenclamide.	2001 May	11311964
Increments in insulin sensitivity during intensive treatment are closely correlated with decrements in glucocorticoid receptor mRNA in skeletal muscle from patients with Type II diabetes.	2001 Nov	11672459
Determination of gliclazide in pharmaceutical preparations by capillary gas chromatography with cool on-column injection and elimination of the matrix effect.	2001 Nov-Dec	11767133
Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.	2001 Oct	11678792
Structural basis for the interference between nicorandil and sulfonylurea action.	2001 Oct	11574406
[Toxicological analysis in the dawn of the third millenium].	2001 Sep-Oct	11602391
Gliclazide-induced hepatitis, hemiplegia and dysphasia in a suicide attempt.	2001 Sep-Oct	11592575
A novel simple method for the investigation of drug binding to the K(ATP) channel sulfonylurea receptor.	2002 Aug 15	12202259
High-frequency insulin pulsatility and type 2 diabetes: from physiology and pathophysiology to clinical pharmacology.	2002 Dec	12703061
[Molecular mechanisms of insulin secretion].	2002 Dec	12703060
Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control.	2002 Dec	12489066
Gliclazide directly inhibits arginine-induced glucagon release.	2002 Dec	12475779
Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells.	2002 Dec	12409500
Trends in oral antihyperglycemic and insulin use in the Nova Scotia senior population (1993-1999).	2002 Fall	12422249
Family physicians' and general practitioners' approaches to drug management of diabetic hypertension in primary care.	2002 Feb	11882098
Adenosine triphosphate-sensitive potassium (K(ATP)) channel activity is coupled with insulin resistance in obesity and type 2 diabetes mellitus.	2002 Feb	11868613
New trends in the development of oral antidiabetic drugs.	2002 Jan	11860348
Antiaggregatory activity of hypoglycaemic sulphonylureas.	2002 Jul	12136403
Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry.	2002 Jun 15	12015271
Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers.	2002 May	12015789
Effect of gliclazide on islet transplants.	2002 Nov	12431578
Gateways to Clinical Trials.	2002 Sep	12428432
Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes.	2002 Sep	12207812
Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.	2003 Feb	12580986
Pharmacokinetic and pharmacodynamic characterization of gliclazide in healthy volunteers.	2003 Jul	12934650
The application of the convective diffusion model and the film equilibrium model to surfactant-facilitated dissolution of gliclazide.	2003 Jul	12885387
Spectrofluorimetric and spectrophotometric determination of gliclazide in pharmaceuticals by derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole.	2003 Mar-Apr	12723907
Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis.	2003 Nov	14693302
Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.	2003 Nov	14632720
[Medication of the month. Gliclazide modified release (Uni Diamicron)].	2003 Oct	14677526
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.	2003 Oct	14614647
Monotherapy of type 2 diabetes with once-daily gliclazide modified release in primary care.	2003 Oct	14581160
Reflex epilepsy and non-ketotic hyperglycemia.	2003 Sep	14684353

Patents

Sample Use Guides

In Vivo Use Guide

The daily dose may vary from 1 to 4 tablets per day, i.e. from 30 to 120 mg taken orally in a single intake at breakfast time.

Route of Administration: Oral

In Vitro Use Guide

Gliclazide blocked whole-cell murine beta-cell Katp currents with an IC50 of 184 +/- 30 nmol/l (n = 6-10) but was much less effective in rat cardiac and smooth muscle (IC50s of 19.5 +/- 5.4 micromol/l (n = 6-12) and 37.9 +/- 1.0 micromol/l (n = 5-10), respectively). In all three tissues, the action of the drug on whole-cell Katp currents was rapidly reversible. In inside-out patches on beta-cells, gliclazide (1 micromol/l) produced a maximum of 66 +/- 13 % inhibition (n = 5), compared with more than 98 % block in the whole-cell configuration.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:40:52 GMT 2025` Edited by `admin` on `Mon Mar 31 19:40:52 GMT 2025`
Record UNII	G4PX8C4HKV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DIAMICRON

Preferred Name

English

GLICLAZIDE

Official Name

English

SE 1702

Code

English

BENZENESULFONAMIDE, N-(((HEXAHYDROCYCLOPENTA(C)PYRROL-2(1H)-YL)AMINO)CARBONYL)-4-METHYL-

Systematic Name

English

SE-1702

Code

English

gliclazide [INN]

Common Name

English

GLICLAZIDE [MI]

Common Name

English

J3.151H

Code

English

Gliclazide [WHO-DD]

Common Name

English

S-1702

Code

English

NSC-758673

Code

English

GLICLAZIDE [EP MONOGRAPH]

Common Name

English

S-852

Code

English

GLICLAZIDE [JAN]

Common Name

English

1-(3-AZABICYCLO(3.3.0)OCT-3-YL)-3-(P-TOLYLSULFONYL)UREA

Common Name

English

GLIMICRON

Brand Name

English

GLICLAZIDE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C97936